## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.5% below STRENGTH zone (4.0-10.0%); PEG 2.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. CooperCompanies appoints Walt Rosebrough to board in deal with Browning West**
- Source: Investing.com India | 20251223T132751 | Bullish | Relevance: 100%
- CooperCompanies (NASDAQ:COO) has appointed Walter "Walt" M. Rosebrough, Jr. as an independent director, effective January 3, 2026, following a cooperation agreement with Browning West, LP. Rosebrough, CEO Emeritus of STERIS plc, will join the Corporate Governance & Nominating Committee, with consideration for him to become Chair by the end of 2026. This move comes as CooperCompanies' stock has gained 20.6% over the past six months, reflecting recent financial outperformances and positive analyst revisions.

**2. Baldwin Wealth Partners LLC MA Sells 141,836 Shares of The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251222T220748 | Somewhat-Bullish | Relevance: 100%
- Baldwin Wealth Partners LLC MA significantly reduced its stake in The Cooper Companies (NASDAQ:COO) by selling 141,836 shares, retaining 25,555 shares valued at $1.75 million. The Cooper Companies exceeded Q3 earnings and revenue expectations, and its board approved a $2.0 billion share buyback program. Meanwhile, institutional investors show mixed activity in their holdings of COO, and analysts have issued varied price targets for the stock.

**3. Cynthia Lucchese Acquires 1,784 Shares of Cooper Companies (NASDAQ:COO) Stock**
- Source: MarketBeat | 20251223T223719 | Bullish | Relevance: 100%
- Director Cynthia Lucchese recently purchased 1,784 shares of Cooper Companies (NASDAQ:COO) stock for $149,963.04, increasing her total ownership to 9,445 shares. This transaction occurred amidst strong quarterly earnings that surpassed analyst estimates and the company's announcement of a $2.00 billion stock buyback program. The company also appointed Walter M. Rosebrough Jr. to its board and entered a cooperation agreement with activist investor Browning West, signaling potential governance shifts.

**4. Former Steris CEO takes board role at California medical device company**
- Source: Crain's Cleveland Business | 20251223T180741 | Bullish | Relevance: 100%
- Walter M. Rosebrough Jr., former CEO of Steris plc, has been appointed as an independent director at CooperCompanies (Nasdaq: COO), a California-based medical device company. This appointment follows a cooperation agreement with activist investor Browning West LP, which urged changes due to alleged underperformance. Rosebrough is also being considered for the board chair position by the end of 2026, and his proven track record is expected to enhance long-term shareholder value.

**5. Cooper Companies appoints Rosebrough, Jr. to its Board of Directors**
- Source: TipRanks | 20251223T140754 | Bullish | Relevance: 100%
- Cooper Companies (COO) has appointed Walter Rosebrough, Jr. as an independent director to its Board, effective January 3, 2026, stemming from a cooperation agreement with Browning West. Rosebrough will join the Corporate Governance & Nominating Committee, and the Board will consider appointing him as Chair by the end of 2026. Additionally, a new independent director with medical technology experience will be appointed with Browning West's mutual agreement.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($1.04M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Analyst sentiment positive (10 raises, avg +14%). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.5B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 16.8 |
| Current P/E | 18.4 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.7% to 2.5% (-5.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >4.0% for momentum thesis). MRS_5 (-1.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.6% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.54% (CS: 78) | Neutral |
| RSI_14 | 65.2 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $82.88
- **Stop Loss:** $78.52 (5.3% risk)
- **Target:** $87.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 275
- **Position Value:** $22,792.00
- **Portfolio %:** 22.79%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*